Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation

Glycoconjugate Journal

Volumn 33, Issue 3, 2016, Pages 345-358

  Van Scherpenzeel, Monique ^a   Willems, Esther ^a   Lefeber, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Congenital disorders of glycosylation; Glycomics; Protein specific glycosylation; Transferrin

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; PLASMA PROTEIN; TRANSFERRIN;

ARTICLE; CONGENITAL DISORDER OF GLYCOSYLATION; DIAGNOSTIC TEST; ENVIRONMENTAL FACTOR; ENZYME ANALYSIS; GENE IDENTIFICATION; GLYCOBIOLOGY; HEREDITY; HUMAN; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; BLOOD; CHEMISTRY; MOLECULAR DIAGNOSIS; PROCEDURES;

BIOMARKERS; CONGENITAL DISORDERS OF GLYCOSYLATION; GLYCOPROTEINS; HUMANS; MASS SPECTROMETRY; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84953275208     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-015-9639-x     Document Type: Article

References (126)

1. Mechref, Y., et al.: Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis 33(12), 1755–1767 (2012)
2. Miwa, H.E., et al.: The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj. J. 29(8–9), 609–618 (2012)
3. Büll, C., et al.: Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol. Cancer Ther. 12(10), 1935–1946 (2013)
4. Gornik, O., Lauc, G.: Glycosylation of serum proteins in inflammatory diseases. Dis. Markers 25(4–5), 267–278 (2008)
5. Schedin‐Weiss, S., Winblad, B., Tjernberg, L.O.: The role of protein glycosylation in Alzheimer disease. FEBS J. 281(1), 46–62 (2014)
6. Bunn, H.F., Gabbay, K.H., Gallop, P.M.: The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200(4337), 21–27 (1978)
7. Thanabalasingham, G., et al.: Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 62(4), 1329–1337 (2013)
8. Freeze, H.H., et al.: Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am. J. Hum. Genet. 94(2), 161–175 (2014)
9. Jaeken, J.: CDG nomenclature: time for a change! Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 825–826 (2009)
10. Jaeken, J., van den Heuvel L.: Congenital disorders of glycosylation, in physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Springer. p. 483–512 (2014)
11. Hennet, T.: Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochimica et Biophysica Acta (BBA)-General Subjects 1820(9), 1306–1317 (2012)
12. Scott, K., et al.: Congenital disorders of glycosylation: new defects and still counting. J. Inherit. Metab. Dis. 37(4), 609–617 (2014)
13. Grünewald, S., Matthijs, G., Jaeken, J.: Congenital disorders of glycosylation: a review. Pediatr. Res. 52(5), 618–624 (2002)
14. Wolfe, L.A., Krasnewich, D.: Congenital disorders of glycosylation and intellectual disability. Developmental disabilities research reviews 17(3), 211–225 (2013)
15. Wada, Y.: Mass spectrometry for congenital disorders of glycosylation, CDG. J. Chromatogr. B 838(1), 3–8 (2006)
16. Morelle, W., Michalski, J.-C.: Analysis of protein glycosylation by mass spectrometry. Nat. Protoc. 2(7), 1585–1602 (2007)
17. Guillard, M., et al.: Automated measurement of permethylated serum N-glycans by MALDI–linear ion trap mass spectrometry. Carbohydr. Res. 344(12), 1550–1557 (2009)
18. Sturiale, L., Barone, R., Garozzo, D.: The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. J. Inherit. Metab. Dis. 34(4), 891–899 (2011)
19. Lacey, J.M., et al.: Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin. Chem. 47(3), 513–518 (2001)
20. Tegtmeyer, L.C., et al.: Multiple phenotypes in phosphoglucomutase 1 deficiency. N. Engl. J. Med. 370(6), 533–542 (2014)
21. Matthijs, G., et al.: Approaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG. Glycoconj. J. 30(1), 67–76 (2013)
22. Jaeken, J.: Congenital disorders of glycosylation. Ann. N. Y. Acad. Sci. 1214(1), 190–198 (2010)
23. Jaeken, J., et al.: Sialic acid-deficient serum and cerebrospinal fluid transferrin in a newly recognized genetic syndrome. Clin. Chim. Acta 144(2), 245–247 (1984)
24. Helander, A., Husa, A., Jeppsson, J.-O.: Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin. Chem. 49(11), 1881–1890 (2003)
25. Carchon, H.A., et al.: Diagnosis of congenital disorders of glycosylation by capillary zone electrophoresis of serum transferrin. Clin. Chem. 50(1), 101–111 (2004)
26. Sanz‐Nebot, V., et al.: Characterization of transferrin glycoforms in human serum by CE-UV and CE-ESI-MS. Electrophoresis 28(12), 1949–1957 (2007)
27. Lefeber, D.J., Morava, E., Jaeken, J.: How to find and diagnose a CDG due to defective N-glycosylation. J. Inherit. Metab. Dis. 34(4), 849–852 (2011)
28. Albahri, Z., et al.: Genetic variants of transferrin in the diagnosis of protein hypoglycosylation. J. Inherit. Metab. Dis. 28(6), 1184–1188 (2005)
29. Zühlsdorf, A., et al.: Transferrin variants: Pitfalls in the diagnostics of congenital disorders of glycosylation. Clin. Biochem. 48(1), 11–13 (2015)
30. Kühnl, P., Spielmann, W.: Transferrin: evidence for two common subtypes of the TfC allele. Hum. Genet. 43(1), 91–95 (1978)
31. van Scherpenzeel, M., et al.: High-resolution Qtof-MS glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. Translational Res, (2015)
32. Jaeken, J.: Congenital disorders of glycosylation (CDG): it’s (nearly) all in it! J. Inherit. Metab. Dis. 34(4), 853–858 (2011)
33. Gao, N., Lehrman, M.A.: Analyses of dolichol pyrophosphate–linked oligosaccharides in cell cultures and tissues by fluorophore-assisted carbohydrate electrophoresis. Glycobiology 12(5), 353–360 (2002)
34. Timal, S., et al.: Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum. Mol. Genet. 21(19), 4151–4161 (2012)
35. Wopereis, S., et al.: Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N-and O-glycan biosynthesis defects. Clin. Chem. 53(2), 180–187 (2007)
36. Bruneel, A., et al.: Two-dimensional gel electrophoresis of apolipoprotein C-III and other serum glycoproteins for the combined screening of human congenital disorders of O-and N-glycosylation. PROTEOMICS-Clinical Applications 1(3), 321–324 (2007)
37. Wada, Y., Tajiri, M., Yoshida, S.: Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal. Chem. 76(22), 6560–6565 (2004)
38. Guillard, M., et al.: Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin. Chem. 57(4), 593–602 (2011)
39. Xia, B., et al.: Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal. Biochem. 442(2), 178–185 (2013)
40. Wada, Y., Kadoya, M., Okamoto, N.: Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. Glycobiology 22(8), 1140–1144 (2012)
41. Faid, V., et al.: A rapid mass spectrometric strategy for the characterization of N-and O-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics 7(11), 1800–1813 (2007)
42. Yen-Nicolaÿ, S., et al.: MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis. PROTEOMICS-Clinical Applications, (2015)
43. Van Scherpenzeel, M., et al.: Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain 137(4), 1030–1038 (2014)
44. Freeze, H.H.: Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 835–840 (2009)
45. De Lonlay, P., Seta, N.: The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 841–843 (2009)
46. Marquardt, T., et al.: Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 94(12), 3976–3985 (1999)
47. Almeida, A., Layton, M., Karadimitris, A.: Inherited glycosylphosphatidyl inositol deficiency: a treatable CDG. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1792(9), 874–880 (2009)
48. Almeida, A.M., et al.: Targeted therapy for inherited GPI deficiency. N. Engl. J. Med. 356(16), 1641–1647 (2007)
49. Freeze, H.H., Aebi, M.: Molecular basis of carbohydrate-deficient glycoprotein syndromes type I with normal phosphomannomutase activity. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1455(2), 167–178 (1999)
50. Janssen, M.C., et al.: Successful liver transplantation and long-term follow-up in a patient with MPI-CDG. Pediatrics 134(1), e279–e283 (2014)
51. Quick, C.B., Fisher, R.A., Harris, H.: A kinetic study of the isozymes determined by the three human phosphoglucomutase loci PGM1, PGM2 and PGM3. Eur. J. Biochem. 42(2), 511–517 (1974)
52. Etzioni, A., et al.: Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation. Am. J. Med. Genet. 110(2), 131–135 (2002)
53. Marquardt, T., et al.: Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J. Pediatr. 134(6), 681–688 (1999)
54. Cagdas, D., et al.: A novel mutation in leukocyte adhesion deficiency type II/CDGIIc. J. Clin. Immunol. 34(8), 1009–1014 (2014)
55. Maeda, Y., et al.: PIG-M transfers the first mannose to glycosylphosphatidylinositol on the lumenal side of the ER. The EMBO journal 20(1–2), 250–261 (2001)
56. Varki, A., et al.: Essentials of glycobiology. 2nd ed. Chapter 13: Cold Spring (2009)
57. Zielinska, D.F., et al.: Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141(5), 897–907 (2010)
58. Medzihradszky, K.F., Kaasik, K., Chalkley, R.J.: Tissue-specific glycosylation at the glycopeptide level. Mol. Cell. Proteomics M115, 050393 (2015)
59. Sadat, M.A., et al.: Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N. Engl. J. Med. 370(17), 1615–1625 (2014)
60. Duplomb, L., et al.: Cohen syndrome is associated with major glycosylation defects. Human molecular genetics, p. ddt630 (2013)
61. Testa, R., et al.: N-Glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One 10(3), e0119983 (2015)
62. Kitazume, S.: Glycosylation of amyloid β precursor protein, pp. 1283–1288. Biology and Medicine, Glycoscience (2015)
63. Albrecht, S., et al.: Glycosylation as a marker for inflammatory arthritis. Cancer Biomark 14, 17–28 (2014)
64. Angata, T., et al.: Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann. N. Y. Acad. Sci. 1253(1), 159–169 (2012)
65. Adamczyk, B., Tharmalingam, T., Rudd, P.M.: Glycans as cancer biomarkers. Biochimica et Biophysica Acta (BBA)-General Subjects 1820(9), 1347–1353 (2012)
66. Ludwig, J.A., Weinstein, J.N.: Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845–856 (2005)
67. Shinohara, Y., Furukawa, J.-I., Miura Y.: Glycome as biomarkers. General Methods Biomarker Res their Appl, p. 111–140 (2015)
68. Kirwan, A., et al.: Glycosylation-based serum biomarkers for cancer diagnostics and prognostics. BioMed Res Int, 2015. (2015)
69. Chu, C.S., et al.: Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics 9(7), 1939 (2009)
70. Song, T., Aldredge, D., Lebrilla, C.B.: A method for in-depth structural annotation of human serum glycans that yields biological variations. Anal. Chem. 87(15), 7754–7762 (2015)
71. Leymarie, N., Zaia, J.: Effective use of mass spectrometry for glycan and glycopeptide structural analysis. Anal. Chem. 84(7), 3040–3048 (2012)
72. Wuhrer, M.: Glycomics using mass spectrometry. Glycoconj. J. 30(1), 11–22 (2013)
73. Stoeckmann, H., et al.: Ultra-high throughput, ultrafiltration-based N-glycomics platform for ultra-performance liquid chromatography (ULTRA3). Analytical Chem, (2015)
74. Callewaert, N., et al.: Noninvasive diagnosis of liver cirrhosis using DNA sequencer–based total serum protein glycomics. Nat. Med. 10(4), 429–434 (2004)
75. Ota, H., et al.: Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch. 433(5), 419–426 (1998)
76. Tangvoranuntakul, P., et al.: Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. 100(21), 12045–12050 (2003)
77. Knezevic, A., et al.: Variability, heritability and environmental determinants of human plasma N-glycome. J. Proteome Res. 8(2), 694–701 (2008)
78. Butler, M., et al.: Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 13(9), 601–622 (2003)
79. Alley, W.R., Mechref, Y., Novotny, M.V.: Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data. Rapid Commun. Mass Spectrom. 23(1), 161–170 (2009)
80. Mechref, Y.: Use of CID/ETD mass spectrometry to analyze glycopeptides. Current Protocols Protein Sci: p. 12.11. 1–12.11. 11 (2012)
81. Wuhrer, M., et al.: Glycoproteomics based on tandem mass spectrometry of glycopeptides. J. Chromatogr. B 849(1), 115–128 (2007)
82. Ma, B., Johnson R.: De novo sequencing and homology searching. Mol. Cell. Proteomics. 11(2): p. O111. 014902 (2012)
83. Khatri, K., et al.: Confident assignment of site-specific glycosylation in complex glycoproteins in a single step. J. Proteome Res. 13(10), 4347–4355 (2014)
84. Whiteaker, J.R., et al.: Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry. Molecular & Cellular Proteomics. 11(6): p. M111. 015347 (2012)
85. Ongay, S., et al.: Glycopeptide enrichment and separation for protein glycosylation analysis. J. Sep. Sci. 35(18), 2341–2372 (2012)
86. Yang, Z., Hancock, W.S.: Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J. Chromatogr. A 1053(1), 79–88 (2004)
87. Wang, Y., Wu, S.-l., Hancock, W.S.: Approaches to the study of N-linked glycoproteins in human plasma using lectin affinity chromatography and nano-HPLC coupled to electrospray linear ion trap—Fourier transform mass spectrometry. Glycobiology 16(6), 514–523 (2006)
88. Trinidad, J.C., et al.: N-and O-glycosylation in the murine synaptosome. Mol. Cell. Proteomics 12(12), 3474–3488 (2013)
89. Picotti, P., Aebersold, R.: Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 9(6), 555–566 (2012)
90. Hong, Q., et al.: Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal. Chem. 85(18), 8585–8593 (2013)
91. Hülsmeier, A.J., Paesold-Burda, P., Hennet, T.: N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol. Cell. Proteomics 6(12), 2132–2138 (2007)
92. Sun, S., Zhang H.: Large-scale measurement of absolute protein glycosylation stoichiometry. Analytical Chem, (2015)
93. Gornik, O., et al.: Change of transferrin sialylation differs between mild sepsis and severe sepsis and septic shock. Intern. Med. 50(8), 861–869 (2011)
94. Kontro, H., et al.: Comparison of sialylated N-glycopeptide levels in serum of pancreatic cancer patients, acute pancreatitis patients, and healthy controls. Proteomics 14(15), 1713–1723 (2014)
95. Abraham, J.: OVA1 test for preoperative assessment of ovarian cancer. Commun. Oncol. 7(6), 249–250 (2010)
96. Stockley, R.A., Turner, A.M.: α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol. Med. 20(2), 105–115 (2014)
97. Comunale, M.A., et al.: Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. (2010)
98. Liang, Y., et al.: Differentially expressed glycosylated patterns of alpha-1-antitrypsin as serum biomarkers for the diagnosis of lung cancer. Glycobiology: p. cwu115 (2014)
99. Arnold, J.N., et al.: Novel glycan biomarkers for the detection of lung cancer. J. Proteome Res. 10(4), 1755–1764 (2011)
100. Saldova, R., et al.: Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17(12), 1344–1356 (2007)
101. Bones, J., et al.: Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J. Proteome Res. 10(3), 1246–1265 (2010)
102. Okuyama, N., et al.: Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 118(11), 2803–2808 (2006)
103. Miyoshi, E., Nakano, M.: Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 8(16), 3257–3262 (2008)
104. Saroha, A., et al.: Altered glycosylation and expression of plasma alpha-1-acid glycoprotein and haptoglobin in rheumatoid arthritis. J. Chromatogr. B 879(20), 1839–1843 (2011)
105. Humphries, J.M., et al.: Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844(5), 1051–1058 (2014)
106. Comunale, M.A., et al.: Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J. Proteome Res. 8(2), 595–602 (2008)
107. Sarrats, A., et al.: Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. PROTEOMICS-Clinical Applications 4(4), 432–448 (2010)
108. Lieberman, J., et al.: Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol. Aging 16(5), 747–753 (1995)
109. Saso, L., et al.: Abnormal glycosylation of α2-macroglobulin, a non-acute-phase protein, in patients with autoimmune diseases. Inflammation 17(4), 465–479 (1993)
110. Mehta, A., Block, T.M.: Fucosylated glycoproteins as markers of liver disease. Dis. Markers 25(4–5), 259–265 (2008)
111. Fardet, L., et al.: Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis & Rheumatism 58(5), 1521–1527 (2008)
112. Yin, H., et al.: Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J. Proteome Res. 13(6), 2887–2896 (2014)
113. Comunale, M.A., et al.: Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J. Proteome Res. 5(2), 308–315 (2006)
114. Balmaña, M., et al.: Identification of potential pancreatic cancer serum markers: increased sialyl-Lewis X on ceruloplasmin. Clin. Chim. Acta 442, 56–62 (2015)
115. Baudin, E., et al.: Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. The Journal of Clinical Endocrinology & Metabolism 88(3), 1107–1111 (2003)
116. Mohamed, M., et al.: Thyroid function in PMM2-CDG: diagnostic approach and proposed management. Mol. Genet. Metab. 105(4), 681–683 (2012)
117. Macchia, P.E., et al.: Thyroid function tests and characterization of thyroxine-binding globulin in the carbohydrate-deficient glycoprotein syndrome type I. The Journal of Clinical Endocrinology & Metabolism 80(12), 3744–3749 (1995)
118. Ross, D.S.: Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease. Endocrinol. Metab. Clin. N. Am. 30(2), 245–264 (2001)
119. Gbormittah, F.O., et al.: Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma. J Proteome Res, (2015)
120. Kakisaka, T., et al.: Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J. Chromatogr. B 852(1), 257–267 (2007)
121. van Reeuwijk, J., et al.: POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42(12), 907–912 (2005)
122. Qiu, Y., et al.: Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 7(4), 1693–1703 (2008)
123. Wang, J., et al.: Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One 8, e70519 (2013)
124. Cheng, Z., et al.: Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharmaceutica Sinica B, (2015)
125. Dieplinger, H., Dieplinger, B.: Afamin—A pleiotropic glycoprotein involved in various disease states. Clin. Chim. Acta 446, 105–110 (2015)
126. Gilgunn, S., et al.: Aberrant PSA glycosylation—a sweet predictor of prostate cancer. Nature Reviews Urology 10(2), 99–107 (2013)